Workflow
Grocery Outlet(GO) - 2025 Q1 - Earnings Call Transcript
2025-05-06 20:30
Grocery Outlet (GO) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Speaker0 Good afternoon, and welcome to Grocery Outlet's call to discuss financial results for the first quarter ended 03/28/2025. Speaking from management on today's call will be Jason Potter, president and chief executive officer and Chris Miller, chief financial officer. Following prepared remarks from Jason and Chris, we will open the call for questions. Please note that this conference call is being webcast live and a recording will be ...
Grand Canyon Education(LOPE) - 2025 Q1 - Earnings Call Transcript
2025-05-06 20:30
Grand Canyon Education (LOPE) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Speaker0 Good day, and thank you for standing by. Welcome to the Q1 twenty twenty five Grand Canyon Education Incorporated Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone. You will Speaker1 then hear an automated message advising that you ...
Forrester Research(FORR) - 2025 Q1 - Earnings Call Transcript
2025-05-06 20:30
Forrester Research (FORR) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Speaker0 Good afternoon and thank you for standing by. Welcome to Forrester's First Quarter twenty twenty five Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. Please be advised that today's conference is being recorded. I would now like to turn the conference over to Vice President of Corporate Development and Investor Relations, E ...
Energy Transfer(ET) - 2025 Q1 - Earnings Call Transcript
2025-05-06 20:30
Energy Transfer (ET) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Company Participants Thomas Long - Director & Co-CEOTheresa Chen - MD - Equity ResearchMackie McCrea - Director & Co-CEOJean Ann Salisbury - Managing DirectorSpiro Dounis - DirectorKeith Stanley - DirectorMichael Blum - Managing DirectorManav Gupta - Executive DirectorDylan Bramhall - Group Chief Financial Officer of LE GP, LLCJohn Mackay - VP - Equity ResearchGabriel Moreen - Managing Director Conference Call Participants Jeremy Tonet - Eq ...
Energy Transfer(ET) - 2025 Q1 - Earnings Call Transcript
2025-05-06 20:30
Energy Transfer (ET) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Speaker0 Please note, today's event is being recorded. I would now like to turn the conference over to Tom Long. Please go ahead. Speaker1 Thank you, operator. Good afternoon, everyone, and welcome to the Energy Transfer first quarter twenty twenty five earnings call. Also joined today by Mackie McCree and other members of the senior management team who are here to help answer your questions after our prepared remarks. Hopefully, you saw th ...
Dynavax(DVAX) - 2025 Q1 - Earnings Call Transcript
2025-05-06 20:30
Financial Data and Key Metrics Changes - Dynavax reported its highest ever first quarter net revenue for HEPLISAV B at $65 million, a 36% increase compared to the previous year [5][14] - Total revenues for the first quarter reached $68 million, up 34% year over year [26] - HEPLISAV B gross margin improved to 79% from 77% in the same quarter last year, with expectations of approximately 80% for the full year 2025 [26] - GAAP net loss for the first quarter was $96 million, compared to a net loss of $9 million in the first quarter of the previous year, primarily due to debt refinancing accounting treatment [28][29] - Non-GAAP adjusted EBITDA improved to negative $4 million from negative $7 million year over year [29] Business Line Data and Key Metrics Changes - The retail segment for HEPLISAV B saw a significant year-over-year growth of approximately 70% in the first quarter [14] - HEPLISAV B's estimated U.S. market share rose to 43% in Q1, up from 41% in the same period last year [16] - The company executed over 85% of its $200 million share repurchase program as of May 5, 2025 [11][30] Market Data and Key Metrics Changes - The total market dose volume for hepatitis B vaccines increased approximately 16% year over year [13] - The company anticipates HEPLISAV B market opportunity to peak at over $900 million by 2030, capturing at least 60% market share [17] Company Strategy and Development Direction - Dynavax aims to leverage its vaccine adjuvant technology, CpG 1018, to advance its development pipeline, including shingles and plague vaccine programs, as well as new programs in pandemic influenza and Lyme disease [5][9][10] - The company maintains a disciplined approach to capital allocation while evaluating external opportunities to generate long-term growth [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving the top half of the annual revenue guidance range for HEPLISAV B due to strong early performance [5][32] - The company expects continued market share gains throughout 2025, supported by strong growth in retail and other key customer segments [17] Other Important Information - The company plans to initiate a phase one/two trial for its pandemic influenza adjuvant program in the coming weeks [9][24] - The Lyme disease vaccine program is expected to enter clinical trials in 2027, with a focus on fewer doses or less frequent boosters compared to current candidates [10] Q&A Session Summary Question: Why not officially raise the lower end of guidance if confidence in hitting the upper half? - Management stated it is prudent to maintain the overall guidance range as the year is only one quarter in [35] Question: How does capital allocation and business development fit into the long-term strategy? - Management emphasized a balanced strategy focusing on leveraging core assets while also returning capital to shareholders through share buybacks [36][38] Question: What contributed to less seasonality in the winter of 2024-2025? - Management noted a purposeful focus by retailers on non-flu vaccines, including hepatitis B, contributing to growth [42] Question: Will the upcoming shingles data release be sufficient for a go/no-go decision? - Management clarified that while the data is important, a more comprehensive data package will be needed for pivotal trial decisions [44][46] Question: Any issues with discussions with the FDA regarding new vaccine requirements? - Management indicated that they have not faced significant issues and expect to engage with the FDA at the appropriate stages [50][56] Question: How does the company view the competitive landscape for the Lyme vaccine? - Management believes their product profile will support a leading market share position due to a more approachable dosing regimen [58]
Day One Biopharmaceuticals pany(DAWN) - 2025 Q1 - Earnings Call Transcript
2025-05-06 20:30
Day One Biopharmaceuticals (DAWN) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Speaker0 Hello, ladies and gentlemen, and welcome to the DayOne Biopharmaceuticals First Quarter twenty twenty five Financial and Operating Results Conference Call. At this time, all participants are in a listen only mode. Later, we will conduct a question and answer session. Please be advised that this conference call is being recorded. I would now like to turn the call over to Joy Peroni, Senior Vice President of Finance and ...
Cytokinetics(CYTK) - 2025 Q1 - Earnings Call Transcript
2025-05-06 20:30
Cytokinetics (CYTK) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Company Participants Diane Weiser - Senior Vice President of Corporate Communications & Investor RelationsRobert Blum - President and CEOAndrew Callos - Executive VP & Chief Commercial OfficerFady Malik - Executive Vice President of Research & DevelopmentStuart Kupfer - Senior VP & Chief Medical OfficerIsaac Ciechanover - EVP, Corporate Development and Chief Business OfficerSung Lee - Executive VP & CFOSean McCutcheon - Vice President - Biot ...
Cytokinetics(CYTK) - 2025 Q1 - Earnings Call Transcript
2025-05-06 20:30
Cytokinetics (CYTK) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Company Participants Diane Weiser - Senior Vice President of Corporate Communications & Investor RelationsRobert Blum - President and CEOAndrew Callos - Executive VP & Chief Commercial OfficerFady Malik - Executive Vice President of Research & DevelopmentStuart Kupfer - Senior VP & Chief Medical OfficerIsaac Ciechanover - EVP, Corporate Development and Chief Business OfficerSung Lee - Executive VP & CFOSean McCutcheon - Vice President - Biot ...
Cytokinetics(CYTK) - 2025 Q1 - Earnings Call Transcript
2025-05-06 20:30
Cytokinetics (CYTK) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Speaker0 Good afternoon, and welcome to Cytokinetics First Quarter twenty twenty five Conference Call. At this time, I would like to inform you that this call is being recorded and that all participants are in a listen only mode. At the company's request, we will open the call to questions after the presentation. We will allow for only one question per participant. I will now turn the call over to Diane Weiser, Cytokinetics' Senior Vice Pres ...